Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
August 08, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
August 07, 2024 16:02 ET
|
Allogene Therapeutics, Inc.
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024Patient Screening for Minimal Residual Disease (MRD) and...
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
July 31, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
July 01, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton...
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
June 20, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s...
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
May 23, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13, 2024 16:47 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
May 13, 2024 16:01 ET
|
Allogene Therapeutics, Inc.
Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell...
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
April 26, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC...